Adam M. Brufsky, MD, PhD

Articles

Dr. Brufsky on Cobimetinib Plus Paclitaxel in TNBC

January 4th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Dr. Brufsky on Anastrozole Versus Tamoxifen in DCIS

June 3rd 2015

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, compares the use of anastrozole to tamoxifen in patients with ductal carcinoma in situ (DCIS).

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

August 21st 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Dr. Brufsky Discusses Future Research into Bisphosphonates

August 11th 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

Dr. Brufsky on Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer

July 11th 2014

Adam M. Brufsky, MD, PhD, discusses the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.

Dr. Brufsky Discusses the tnAcity Trial in TNBC

December 13th 2013

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Dr. Brufsky Advises Doctors on Avastin for Breast Cancer

November 18th 2011

Dr. Adam Brufsky from the University of Pittsburgh School of Medicine Advises Doctors on Bevacizumab (Avastin) for Breast Cancer

Dr. Brufsky Discusses Bevacizumab Benefits in TNBC

November 15th 2011

Dr. Adam Brufsky from University of Pittsburgh School of Medicine, Discusses Bevacizumab Benefits in TNBC